{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:44:41Z","timestamp":1697445881010},"reference-count":89,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,27]],"date-time":"2013-01-27T00:00:00Z","timestamp":1359244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Nurse Practitioners"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder that affects almost 24 million Americans. Healthcare providers often do not initiate and\/or intensify therapy appropriately during patient visits, which may be due, in part, to a lack of understanding of the new diabetes medications. This review focuses on means by which primary care nurse practitioners (NPs) might evaluate the utility of pharmacologic agents based upon their relation to the pathogenesis of T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources<\/jats:title><jats:p>The evidence used in developing this review included evidence\u2010based reviews, clinical trials, cohort studies, position statements, and guidelines. The authors obtained relevant reports through a computerized search of the literature using PubMed, MEDLINE, and other search engines and scanning syllabi from national and international meetings on the subject of type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Medications used to manage T2DM utilize different pharmacologic approaches. These include stimulating insulin production, reducing hepatic gluconeogenesis, slowing polysaccharide digestion, and increasing insulin sensitivity in muscle, liver, and fat to achieve euglycemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for practice<\/jats:title><jats:p>Patients with T2DM should be treated to their lowest targeted glycemic goals as soon as they are diagnosed as safely and as rationally as possible. NPs in primary care practice can facilitate more effective diabetes management.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1745-7599.2012.00736.x","type":"journal-article","created":{"date-parts":[[2012,5,4]],"date-time":"2012-05-04T09:13:35Z","timestamp":1336122815000},"page":"65-76","source":"Crossref","is-referenced-by-count":1,"title":["Putting medications where they belong: Practical advice for managing type 2 diabetes in clinical practice"],"prefix":"10.1111","volume":"25","author":[{"given":"Jeff","family":"Unger","sequence":"first","affiliation":[{"name":"Catalina Research Institute  Chino California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Hinnen","sequence":"additional","affiliation":[{"name":"Mid America Diabetes Associates  Wichita Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Capella University College of Nursing  Pearland Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Parkin","sequence":"additional","affiliation":[{"name":"CG Parkin Communications, Inc.  Las Vegas Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,27]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2007.07.005"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9017"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.17.3.183"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000219"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00602.x"},{"key":"e_1_2_4_8_1","doi-asserted-by":"crossref","unstructured":"Boden G.(1999).Free fatty acids insulin resistance and type 2 diabetes mellitus.Proceedings of the Association of American Physicians 111 241\u2013248.","DOI":"10.1046\/j.1525-1381.1999.99220.x"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39781"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.32.s3.3.x"},{"key":"e_1_2_4_11_1","first-page":"213","article-title":"Slow response to loss of glycemic control in type 2 diabetes mellitus","volume":"9","author":"Brown J. B.","year":"2003","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.7.1535"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.102"},{"key":"e_1_2_4_15_1","volume-title":"National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007","author":"Centers for Disease Control and Prevention","year":"2008"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1409-4"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.10.3575"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91807-X"},{"key":"e_1_2_4_19_1","volume-title":"American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies","author":"DeFronzo R.","year":"2008"},{"key":"e_1_2_4_20_1","doi-asserted-by":"crossref","DOI":"10.2337\/dc08-1984","volume-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care [On\u2010line]","author":"DeFronzo R.","year":"2009"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.6.667"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.1.35"},{"key":"e_1_2_4_23_1","doi-asserted-by":"crossref","unstructured":"DeFronzo R. A. Ferrannini E. Hendler R. Wahren J. &Felig P.(1978b).Influence of hyperinsulinemia hyperglycemia and the route of glucose administration on splanchnic glucose exchange.Proceedings of the National Academy of Sciences of the United States 75 5173\u20135177.","DOI":"10.1073\/pnas.75.10.5173"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(89)90129-7"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111938"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802418851"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902820519"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)83039-8"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.4.0336"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(88)90033-9"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.13.1695"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706245"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1263-9"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69420-8"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.1.61"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365510802207982"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390404"},{"key":"e_1_2_4_40_1","first-page":"550","article-title":"Can family physicians help patients initiate basal insulin therapy successfully?: Randomized trial of patient\u2010titrated insulin glargine compared with standard oral therapy: Lessons for family practice from the Canadian INSIGHT trial","volume":"54","author":"Harris S.","year":"2008","journal-title":"Canadian Family Physician"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905479"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(99)00157-5"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38678.389583.7C"},{"key":"e_1_2_4_45_1","volume-title":"Global guideline for type 2 diabetes. International Diabetes Federation [On\u2010line]","author":"International Diabetes Federation Clinical Guidelines Task Force","year":"2005"},{"key":"e_1_2_4_46_1","volume-title":"Global guideline on self\u2010monitoring of blood glucose in non\u2010insulin treated type 2 diabetes. International Diabetes Federation [On\u2010line]","author":"International Diabetes Federation Clinical Guidelines Taskforce and SMBG International Working Group","year":"2009"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90168-C"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3597(07)80019-6"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.10.2461"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91194-9"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1380"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020904"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2009.01.1954"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0101"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2009.05.010"},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02427280"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00572873"},{"key":"e_1_2_4_61_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8355"},{"key":"e_1_2_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0139-y"},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.3.561"},{"key":"e_1_2_4_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/193229680900300314"},{"key":"e_1_2_4_65_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-9-200111060-00012"},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.384"},{"key":"e_1_2_4_67_1","unstructured":"Polonsky W. H. Fisher L. Schikman C. Hinnen D. Parkin C. Jelsovsky Z. et al. (2010).Structured SMBG significantly reduces HbA1c levels in poorly controlled non\u2010insulin treated type 2 diabetes: Results from the STeP Study. American Diabetes Association 70th Scientific Sessions Orlando Florida 2010."},{"key":"e_1_2_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250100580"},{"key":"e_1_2_4_69_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.13.S1.1"},{"key":"e_1_2_4_70_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.6.540"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113157"},{"issue":"4","key":"e_1_2_4_72_1","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"14","author":"Salpeter S. R.","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.335"},{"key":"e_1_2_4_74_1","first-page":"1S41","article-title":"Glitazones and weight gain","volume":"63","author":"Scheen A.","year":"2002","journal-title":"Annals of Endocrinology (Paris)"},{"key":"e_1_2_4_75_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.1.69"},{"key":"e_1_2_4_76_1","first-page":"E283","article-title":"Impact of lack of suppression of glucagon on glucose tolerance in humans","volume":"277","author":"Shah P.","year":"1999","journal-title":"American Journal of Physiology"},{"key":"e_1_2_4_77_1","doi-asserted-by":"publisher","DOI":"10.2174\/157339908784220705"},{"key":"e_1_2_4_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.60.1.108"},{"key":"e_1_2_4_79_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7750"},{"issue":"2","key":"e_1_2_4_80_1","first-page":"S2","article-title":"The changing landscape of type 2 diabetes: The role of incretin\u2010based therapies in managed care outcomes","volume":"13","author":"Triplitt C.","year":"2007","journal-title":"Journal of Managed Care Pharmacy"},{"key":"e_1_2_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/379069a0"},{"key":"e_1_2_4_82_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"U.K. Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_4_83_1","first-page":"118","volume-title":"Diabetes management in primary care","author":"Unger J.","year":"2007"},{"key":"e_1_2_4_84_1","first-page":"1","volume-title":"Diabetes management in primary care","author":"Unger J.","year":"2007"},{"key":"e_1_2_4_85_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.05.2152"},{"key":"e_1_2_4_86_1","volume-title":"Recommendations for regulatory action for rosiglitazone and rosiglitazone containing products. US Food and Drug Administration [On\u2010line]","author":"U.S. Food and Drug Administration","year":"2010"},{"key":"e_1_2_4_87_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.10.1737"},{"key":"e_1_2_4_88_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.1.327"},{"key":"e_1_2_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90192-4"},{"key":"e_1_2_4_90_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00003"}],"container-title":["Journal of the American Academy of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1745-7599.2012.00736.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1745-7599.2012.00736.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T19:27:57Z","timestamp":1697398077000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1745-7599.2012.00736.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,27]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1745-7599.2012.00736.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1745-7599.2012.00736.x","archive":["Portico"],"relation":{},"ISSN":["1041-2972","1745-7599"],"issn-type":[{"value":"1041-2972","type":"print"},{"value":"1745-7599","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,27]]}}}